REG - OptiBiotix Health - Development agreement signed with CSL <Origin Href="QuoteRef">OPTIO.L</Origin>

OptiBiotix HealthAnnouncement

20/11/2015 07:01

RNS Number : 3614G
OptiBiotix Health PLC
20 November 2015
20 November 2015
OptiBiotix Health plc
("OptiBiotix"orthe Company")
Development Agreement signed withCentro Sperimentale del Latte
OptiBiotixHealthplc(AIM: OPTI),alifesciencesbusinessdevelopingproducts totackleobesity,high
cholesterolanddiabetes, announcesthatithas entered into a development agreement with Centro Sperimentale Del Latte ("CSL") to synthesise and purify novel oligosaccharides (carbohydrates that consists of a small number of sugars)from microbial strains. CSL which is based in Italy, researches, develops, manufactures and distributes probiotics, starter cultures, moulds and yeasts for the pharmaceutical, nutraceutical, dairy, food and agricultural sectors all over the world.
The agreement provides OptiBiotix with development funding for the programme and extends the Company's OptiBiotic technology platform to a wider range of microbial species.
StephenO'Hara,CEOofOptiBiotix,commented:"This development agreement reflects the progress we have made with our OptiBiotic technology platform. Increasing the number of microbial species is an exciting extension of our existing programme which broadens the range of product and partner opportunities. We are particularly pleased that CSL has recognised the opportunity presented by this work and has included its own strains in the development programme".
OptiBiotix Health plc
www.optibiotix.com
Stephen O'Hara, Chief Executive
Contact via Walbrook below


Cairn Financial Advisers LLP
Tel: 020 7148 7900
Liam Murray / Avi Robinson



Hybridan LLP (Joint Broker)
Claire Louise Noyce
Tel: 020 3713 4581
Peterhouse Corporate Finance Ltd (Joint Broker)
Tel: 020 7469 0936
Lucy Williams / Duncan Vasey



Walbrook PR Ltd
Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy
Mob: 07876 741 001
Mike Wort
Mob: 07900 608 002


About OptiBiotix Health PLC - www.optibiotix.com 
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease. 
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes. 
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen and OptiBiotic platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases. 
About CSLhttp://www.cslitalia.it
CSL, based in Italy, researches, develops, manufactures, and distributes probiotics, starter cultures, moulds and yeasts for the pharmaceutical, nutraceutical, dairy, food and agricultural sectors all over the world. CSL has two production plants in Italy, in the proximity of Milan: Zelo Buon Persico: a pharmaceutical production plant for the production of API and pharmaceutical bulk and Pasturago, for food, nutraceuticals and agriculture industries

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCLLFSRLRLALIE